Adults living with IgA nephropathy, the most common form of glomerulonephritis worldwide, now have a new daily pill designed to slow the disease before it reaches kidney failure. The FDA approved Vanrafia, the brand name for atrasentan, on April 2, 2025, to reduce proteinuria in adults with primary IgA nephropathy who face a high risk of rapid disease progression. The approval arrived alongside a separate accelerated approval for Voyxact, a different drug targeting the same condition, making 2025 a rare year in which two distinct therapies reached the market for a single kidney disease that previously had few targeted treatments.
Why a daily pill for IgA nephropathy changes the treatment calculus
IgA nephropathy damages the kidneys when abnormal immunoglobulin A deposits trigger inflammation in the glomeruli, the tiny filtering units inside each kidney. Persistent protein leakage into the urine, known as proteinuria, signals ongoing damage and tracks closely with the speed at which patients lose kidney function. Until recently, the standard approach relied on blood-pressure drugs called RAS inhibitors, corticosteroids with significant side effects, and watchful waiting. The arrival of an oral endothelin receptor antagonist like atrasentan gives physicians a targeted mechanism that acts directly on the cells lining kidney blood vessels to reduce protein leakage.
The practical question is whether this oral pill will stay confined to specialty nephrology clinics or move into broader prescribing. Atrasentan requires monitoring for fluid retention, a known class effect of endothelin antagonists, which means clinicians must watch for weight gain, edema, and heart-failure signals. That monitoring burden could keep initial prescribing tethered to nephrologists for the near term. A shift toward primary-care prescribing within 18 months of approval looks unlikely unless clear safety protocols and simple monitoring checklists emerge from professional societies. For now, patients diagnosed with IgA nephropathy should expect their nephrologist, not their primary-care doctor, to evaluate whether Vanrafia fits their risk profile.
ALIGN trial data and FDA evidence for Vanrafia and Voyxact
The clinical case for Vanrafia rests on the ALIGN trial, a randomized study whose results were published in the New England Journal. The trial enrolled adults already taking maximally tolerated RAS inhibitors and measured changes in the urine protein-to-creatinine ratio, the standard surrogate for kidney-damage progression. Patients had to meet specific thresholds for estimated glomerular filtration rate (eGFR) and proteinuria at baseline, ensuring the study population reflected those at genuine risk of advancing to dialysis or transplant. The ALIGN data showed clear reductions in proteinuria among patients randomized to atrasentan compared with placebo, supporting the idea that endothelin blockade can meaningfully alter short-term disease activity.
The FDA’s own review documents confirm the drug’s scope and limitations. According to the agency’s trial snapshot for Vanrafia, the approved indication is specifically to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid progression. The snapshot also notes enrollment criteria tied to eGFR and proteinuria levels, along with background RAS inhibitor therapy as a prerequisite. Side effects related to fluid retention appear prominently in the safety profile, reinforcing the need for clinical monitoring and careful dose adjustments in patients with borderline cardiac function.
Vanrafia did not arrive alone. The FDA also granted accelerated approval to Voyxact, known generically as sibeprenlimab, for the same disease. That approval, listed on the agency’s 2025 approvals page, was based on proteinuria reduction as a surrogate endpoint rather than on definitive kidney outcomes. Because Voyxact received accelerated rather than traditional approval, its manufacturer must complete a confirmatory trial called VISIONARY to verify that the proteinuria benefit translates into preserved kidney function over time. Both drugs share the same surrogate endpoint, but they work through entirely different biological pathways: atrasentan blocks endothelin receptors on vascular and mesangial cells, while sibeprenlimab targets upstream immune signaling that drives the production of the abnormal IgA deposits implicated in the disease.
Gaps in long-term kidney protection and unanswered prescribing questions
The biggest open question for both drugs is whether cutting protein in the urine actually prevents kidney failure over years, not just months. Proteinuria reduction is an accepted surrogate in nephrology because it correlates with slower eGFR decline, but no completed trial for either Vanrafia or Voyxact has yet demonstrated hard endpoints like delayed dialysis, reduced transplant need, or lower mortality. The VISIONARY confirmatory trial for Voyxact will eventually address this gap for sibeprenlimab, and ongoing follow-up from the ALIGN program should provide longer-term eGFR data for atrasentan. Until those results arrive, clinicians and patients are placing a well-informed bet rather than acting on definitive proof of kidney preservation.
Head-to-head comparisons between the two drugs do not exist. The FDA materials and the published ALIGN results offer no direct data on whether one agent delivers greater proteinuria reductions, superior tolerability, or better long-term kidney outcomes. In practice, nephrologists are likely to individualize therapy based on clinical factors such as baseline eGFR, degree of proteinuria, comorbid heart disease, and prior immunosuppressive exposure. Some patients may be steered toward Vanrafia if they can be closely monitored for fluid retention and already have substantial vascular risk factors under control. Others may be better candidates for Voyxact if their clinicians prioritize targeting the upstream immune drivers of abnormal IgA production, especially in the context of prior steroid toxicity.
Cost, insurance coverage, and logistics will also shape real-world uptake. Both therapies are specialty products that typically require prior authorization, documentation of high-risk IgA nephropathy, and confirmation that standard measures such as RAS inhibition and blood-pressure control have been optimized. For patients, that can translate into delays between diagnosis and treatment initiation, along with frequent laboratory visits for proteinuria and eGFR monitoring. How payers respond to having two branded options in the same niche disease area remains uncertain and may influence which drug becomes the default choice.
For now, the emergence of Vanrafia and Voyxact marks a turning point in a field that long relied on non-specific immunosuppression and supportive care. Patients with IgA nephropathy who once heard only about “watchful waiting” and eventual dialysis can now discuss targeted therapies aimed at slowing the disease much earlier in its course. Yet the optimism is tempered by the reality that both approvals hinge on surrogate measures, not on hard kidney outcomes. The next several years of follow-up data and confirmatory trials will determine whether these drugs merely shift lab numbers or truly change the natural history of IgA nephropathy.
In the meantime, shared decision-making will be essential. Patients will need clear explanations of what proteinuria means, how much benefit is reasonably expected, and what kinds of side effects or monitoring burdens accompany each option. Nephrologists will have to balance enthusiasm for novel mechanisms with caution about long-term safety signals that may only emerge as broader populations start treatment. If future evidence confirms that sustained proteinuria reductions with atrasentan or sibeprenlimab reliably translate into preserved kidney function, 2025 may be remembered as the year IgA nephropathy care moved decisively from reactive to proactive medicine.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
